Guangzhou Hengnuokang Pharmaceutical Technology

Guangzhou Hengnuokang Pharmaceutical Technology is a clinical-stage biotechnology company focused on the development of innovative small molecule drugs. Headquartered in Guangzhou, China, the company targets high-impact therapeutic areas including infectious diseases, central nervous system (CNS) disorders, and fibrosis. Its pipeline features several candidates in clinical development, notably HNK-010 for influenza and HNK-001 for chronic hepatitis B. Hengnuokang's R&D strategy emphasizes the creation of Best-in-Class or First-in-Class therapies through its proprietary chemical synthesis and screening platforms. The company is supported by prominent venture capital investors and led by industry veterans with extensive global drug development experience.